ARTICLE | Clinical News
EPI-506: Phase I/II started
December 7, 2015 8:00 AM UTC
Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C. Product: EPI-506 Business: Cancer Molecular target: Androgen receptor Description: Selective blocker of the N-terminus of the androgen recepto...